Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of intranasal CVP-NASVAC vaccine in liver-transplanted patients
jRCTs061250043Phase 2Recruiting
- Sponsor
- Japan Society for the Promotion of Science
- Start
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ABX203 in hepatitis B (HBV), sponsored by Japan Society for the Promotion of Science. Primary endpoints: Induction and maintenance of anti-HBs antibodies and Total administered dose of HBIG. Started May 2026; status: recruiting.
02
Drugs
ABX203
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on jRCTs061250043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061250043.